Compare · AXGN vs NUWE
AXGN vs NUWE
Side-by-side comparison of Axogen Inc. (AXGN) and Nuwellis Inc. (NUWE): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AXGN and NUWE operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- AXGN is the larger of the two at $2.16B, about 1688.5x NUWE ($1.3M).
- Over the past year, AXGN is up 258.0% and NUWE is down 98.5% - AXGN leads by 356.5 points.
- NUWE has been more active in the news (8 items in the past 4 weeks vs 2 for AXGN).
- AXGN has more recent analyst coverage (8 ratings vs 1 for NUWE).
- Company
- Axogen Inc.
- Nuwellis Inc.
- Price
- $40.63+2.80%
- $0.49-17.40%
- Market cap
- $2.16B
- $1.3M
- 1M return
- -4.72%
- -56.65%
- 1Y return
- +258.02%
- -98.50%
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NASDAQ
- NASDAQ
- IPO
- News (4w)
- 2
- 8
- Recent ratings
- 8
- 1
Axogen Inc.
AxoGen, Inc., together with its subsidiaries, develops and markets surgical solutions for physical damage or transection to peripheral nerves. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and Avive Soft Tissue Membrane, a processed human umbilical cord membrane that can be used as a resorbable soft tissue covering to separate tissues in the surgical bed. In addition, the company offers AxoTouch two point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. It provides its products to hospitals, surgery centers, and military hospitals plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons in the United States, Canada, Germany, the United Kingdom and other European countries, South Korea, and internationally. AxoGen, Inc. is headquartered in Alachua, Florida.
Nuwellis Inc.
Nuwellis, Inc., a medical device company, focuses on developing, manufacturing, and commercializing medical devices used in ultrafiltration therapy. The company's products are the Aquadex FlexFlow and Aquadex SmartFlow systems, which are indicated for the treatment of patients suffering from fluid overload who have failed diuretics. Its Aquadex FlexFlow system includes a console, disposable blood set, and catheter. The company sells its products to hospitals and clinics through its direct salesforce in the United States; and through independent specialty distributors primarily in Austria, Brazil, Brunei, Germany, Greece, Hong Kong, India, Israel, Italy, Palestine, Singapore, Spain, Switzerland, Thailand, and the United Kingdom. The company was formerly known as CHF Solutions, Inc. and changed its name to Nuwellis, Inc. in April 2021. Nuwellis, Inc. was founded in 1999 and is headquartered in Eden Prairie, Minnesota.
Latest AXGN
- The Newest Name on Nasdaq Wants to Help the Body Rebuild Itself
- Director Wendell Amy Mcbride exercised 1,647 shares at a strike of $14.85 and sold $70,162 worth of shares (1,647 units at $42.60) (SEC Form 4)
- Director Johnson John sold $477,968 worth of shares (11,050 units at $43.26) and exercised 11,050 shares at a strike of $7.04 (SEC Form 4)
- Director Weiler Kathy Johnson exercised 16,344 shares at a strike of $6.95 and sold $720,623 worth of shares (16,344 units at $44.09) (SEC Form 4)
- Chief Marketing Officer Kemp Jens sold $173,761 worth of shares (4,000 units at $43.44), decreasing direct ownership by 5% to 72,451 units (SEC Form 4)
- CFO Hartley Lindsey Marie sold $45,897 worth of shares (1,051 units at $43.67) and exercised 5,463 shares at a strike of $8.24, increasing direct ownership by 7% to 65,146 units (SEC Form 4)
- Sales VP Quackenbush Doris sold $168,720 worth of shares (3,878 units at $43.51), decreasing direct ownership by 4% to 92,416 units (SEC Form 4)
- New insider Quackenbush Doris claimed ownership of 96,294 shares (SEC Form 3)
- TELA Bio Announces Strategic Board Refreshment with Four Highly Experienced Commerical Leaders to Accelerate Growth and Drive Path to Profitability; The Company Also Reports Preliminary First Quarter 2026 Revenues
- Axogen, Inc. to Participate in the 2026 Bank of America Global Healthcare Conference
Latest NUWE
- SEC Form FWP filed by Nuwellis Inc.
- Amendment: SEC Form S-1/A filed by Nuwellis Inc.
- SEC Form SD filed by Nuwellis Inc.
- SEC Form S-1 filed by Nuwellis Inc.
- SEC Form 10-Q filed by Nuwellis Inc.
- Nuwellis Announces Successful Completion of FDA Pre-Submission 510(k) Meeting to Expand Aquadex Label
- Nuwellis Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Nuwellis, Inc. Announces First Quarter 2026 Financial Results
- Nuwellis, Inc. To Announce First Quarter 2026 Financial Results on May 12, 2026
- SEC Form 4 filed by Director Waller Gregory D